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Summary Cyclosporin A (Sandimmune) increased the in vitro susceptibility of 'parental' and 'multidrug-
resistant' (MDR) chinese hamster ovary (CHO) cell lines to three anti-tumour drugs: colchicine, daunomycin,
and vincristine. Several immunosuppressive or non-immunosuppressive derivatives of cyclosporin (Cs) were
compared for their ability to sensitise both parental and MDR cells to chemotherapeutic agents. Although
5-10-fold increases of sensitivity to anti-tumour drugs could be obtained for cells of the parental line with
several Cs-derivatives, the largest 'gains' of sensitivity (chemosensitisation) were obtained for the cells of the
MDR line and with only some of the Cs derivatives. The MDR cells employed displayed the typical MDR
phenotype. However, we found no correlation between the immunosuppressive activity of Cs derivatives and
their capacity to reverse MDR and all four possible combinations of these two activities could indeed be
shown among the tested Cs derivatives. This study demonstrates for the first time that some immunosuppres-
sive Cs can be devoid of chemosensitising activity.
Prolonged treatment of tumour cells with an anti-cancer drug
may cause them to become resistant to a variety of drugs
which differ in their mechanism of action, but share the
property ofentering the cells by passive diffusion through the
membrane (Gerlach et al., 1986; Stark, 1986; Gottesman &
Pastan, 1988). This multidrug resistance (MDR) has been
closely linked to the specific amplification of expression of a
particular class of transmembrane glycoprotein called the
P-glycoprotein (Pgp) (Ling & Thompson, 1974; Bech-Hansen
et al., 1975; Kartner et al., 1983; Ueda et al., 1987). The
P-glycoproteins decrease the intracellular concentration of
the anti-cancer drug below its cytostatic threshold by actively
pumping it out of the cell.
Various membrane active agents (calcium antagonists,
local anaesthetics) or compounds reducing intracellular ATP
levels have been shown to interfere with the Pgp function.
The immunosuppressive drug cyclosporin A (CsA, Sandim-
mune) has already been shown to reverse MDR. CsA cor-
rects the daunorubicin resistance in Ehrlich ascites carcinoma
(Slater et al., 1986a) and the daunorubicin and vincristine
resistance in acute lymphatic leukaemia (Slater et al., 1986b).
CsA also enhances the daunorubicin efficacy in murine
hepatoma (Meador et al., 1987), modifies adriamycin and
vincristine resistance in a MDR human lung cancer cell line
(Twentyman et al., 1987), and enhances the cytotoxicity of
etoposide and adriamycin in L1210 leukaemic cells (Osieka et
al., 1986).
Two properties of CsA limit its use as a resistance modify-
ing agent in cancer chemotherapy. They are the immunosup-
pressive potency of the drug and its clinical side-effects,
especially nephrotoxicity, neither of which would be accep-
table in high dose cancer treatment.
It was thus mandatory to search for cyclosporin (Cs)
analogues lacking both these unwanted effects of CsA but
displaying similar or enhanced activity in sensitising MDR
tumours towards anti-cancer drugs. For this purpose, we
established a screening programme for Cs-derivatives using
well known MDR and parental (control) cell lines, i.e. the
chemotherapy resistant and sensitive Chinese hamster ovary
(CHO) cell lines established by Dr V. Ling (Toronto) and
used in many laboratories around the world.
Materials and methods
Cell lines anddrugs
Chinese hamster ovary (CHO) cells were obtained from Dr
V. Ling (Ontario Cancer Research Institute, Toronto,
Canada): a colchicine-resistant cell line (MDR line, CHRC5)
and the parental colchicine-sensitive cell line AUX Bi (Ling
& Thompson, 1974, Bech-Hansen et al., 1975). These cell
lines were grown in culture medium (oxMEM medium supple-
mented with Asn 0.02 mg ml-', vitamins (1 x), penicillin-
streptomycin 100 IU ml', Gln 2 mM and 10% heat
inactivated fetal calf serum (all from Gibco)). Colchicine
(Sandoz), daunomycin (Sigma D-4885), puromycin (Sigma
P-7255), vincristine (Serva 38215) and gramicidin D (Serva
24150) were prepared as stock solutions in culture medium.
Immunosuppression
The degree of immunosuppressive activity of the different Cs
derivatives had been previously assessed in several in vitro
and in vivo models (Hiestand & Gubler, 1988).
Proliferation assay ofCHO cell lines
In preliminary experiments, we measured cell growth by
methods such as 3H-thymidine uptake or a colorimetric assay
(cell mass measurement by hexosaminidase content)
(Koponen et al., 1982), but another colorimetric assay using
MTT (Mosmann, 1983) was found to be the most convenient
for screening large numbers of derivatives. This assay had
also been found very 'feasible' for drug screening with panels
of tumour cell lines (Alley et al., 1988).
Preliminary experiments (not shown) were performed in
order to determine the culture conditions. We chose to
dispense, per well, twice as many MDR cells as parental cells,
so that similar cell numbers, giving optical density (OD)
values in the correct range (0.8-1.4, in the colorimetric
assay), were reached after a 6 day culture.
In 96-well microplates (Costar 3596), 50 gl ofcolchicine (or
another anti-cancer drug) solution were added in culture
medium in triplicate to obtain final concentrations of 0,
0.1-30Lggml-' for the MDR line, and 0, 0.001-0.3gjgml-I
for the parental line. A further down-extension of the dose
range was performed when necessary, i.e. when a Cs
derivative was strongly decreasing the anti-cancer drug IC50
(i.e. the drug dose required to reduce the final OD to 50% of
control).
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The Cs derivatives to be tested were dissolved at 1 mg ml1l
in absolute ethanol (EtOH, Merck) and were tested at
1 jig ml-', with control being treated with the corresponding
ethanol solvent dilutions. The cyclosporin derivatives or con-
trol solutions were added (50jl) to each well, and mixed the
100 ILI cell suspensions (4 x 103 cells ml-' for the parental line
and 8 x 103 cells ml-' for the MDR line) and colchicine
solutions (50 jl) which had been added beforehand.
After a 6-day incubation at 37°C, the final cell number was
measured by a colorimetric assay using MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide;
Sigma) (Mosmann, 1983). First, 100 jl of supernatant were
removed, and then to the remaining cell suspension, 10 IL of
the MTT solution (5 mgml-') were added per well and the
plates incubated for 3 h at 37°C; 100 tLI of solvent (butanol-2,
isopropanol, HCI1 N in volume ratio 16/8/1) were added per
well and the plates shaken until complete dissolution of the
formazan crystals. The OD was read at 540 nm on a plate
reader (Titertek Multiskan). The extent of cell growth was
represented as a function of the anti-cancer drug concentra-
tion (the growth in the absence of anti-cancer drug (Cs or
solvent alone) being taken as 100%).
Data analysis
The anti-cancer drug IC50s were determined from the concen-
tration-response curves: either in the presence of Cs
(IC50 + ), or in its absence (IC50 -) (but in the presence of
the Cs solvent, i.e. ethanol).
The increases of anti-cancer drug sensitivity or 'gain of
sensitivity' brought by each Cs at 1 jig ml-' were given by
the ratio IC50 -/C50 +. These measurements were performed
for both cell lines (parental and MDR), for the various
anti-cancer drugs assayed, and for 1 gml-' Cs.
Results
In our assay system, we studied the effects of CsA and some
of its derivatives at a concentration of 1jLg ml-'. Indeed,
maximum tolerable plasma levels of CsA are in the order of
1-2jgml-' (Kahan et al., 1983). Moreover, none of the Cs
derivatives reported in this paper was toxic by itself at
1 jLg ml-' on parental or MDR CHO cells, no detectable
effect on their growth being detected up to 3 jig ml-' for all
of them, and up to 10jigml- for most of them.
Effect ofCsA, CsH and N-phenylaminothio-carbamoyl-CsA in
combination with the anti-tumour drugs on the growth of
parental and MDR lines
The parental and MDR cell lines were first compared for
sensitivity to colchicine, daunomycin and vincristine, and the
IC50 (as jLg ml-') was determined for each drug. Colchicine,
daunomycin and vincristine inhibited the cell growth at com-
parable concentrations (Figure 1, open and filled circles, for
parental and MDR cells respectively). Gramicidin D and
puromycin required high doses to inhibit the MDR line
(IC50s>50 jgml-', not shown). Figure 1 shows the effect of
CsA, CsH and N-phenylaminothio-carbamoyl-CsA on the
drug resistance of both CHO cell lines (the control growth in
the absence of anti-tumour drug being considered as 100%),
the dose-response curves being established with colchicine,
vincristine and daunomycin. For the potentation of all three
anti-cancer drugs (gains of sensitivity), CsA was the most
active: the vincristine IC50 and daunomycin IC50 of MDR
cells in the presence of CsA even fell below the vincristine
IC50 and daunomycin IC50 of parental line in the absence of
CsA. CsA was also effective on the parental line itself, the
parental gains and MDR gains being respectively 10 and 14
for colchicine, 11 and 47 for daunomycin, and 22 and 77 for
vincristine. The N-phenylaminothio-carbamoyl-CsA was
essentially inactive, the gains of sensitivity being below 2.
CsH, an immunologically inactive derivative of CsA, was
weakly active in our assay, giving parental gains and MDR
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Figure 1 Effect of CsA, CsH and N-phenyl-aminothio-
carbamoyl-CsA on multidrug-resistance. Parental ( 0 AV)
and MDR (* AV) cell lines were cultured with colchicine (a),
vincristine (b) and daunomycin (c) for 6 days in the presence of
CsA (A A), CsH (0 *), N-phenyl-aminothio-carbamoyl-CsA
(V V) at I jig ml-', or the ethanol solvent control (O0). Cell
proliferation is represented as percentage of the control cell
growth, that is growth without Cs and without anti-tumour
drugs, versus anti-tumour drug concentration in igml-' (mean
of four independent experiments in triplicate).
gains of, respectively, 4 and 2.5 for daunomycin, 4.5 and 2
for vincristine, and 6 and 1.2 for colchicine.
Effect ofsome Cs derivatives on resistance to colchicine,
vincristine anddaunomycin
The IC50 ranges for colchicine, vincristine and daunomycin in
our assay were the following, respectively (in ng ml- ):
18.5-53, 50-175 and 14-23.5 for parental line, and
980-3,100, 660-5,900 and 500-2,100 for the MDR line.
The ability of some Cs derivatives with different
immunosuppressive powers to sensitise parental and MDR
CHO cells to the three anti-tumour drugs is shown in Table I
for colchicine, in Table II for vincristine and in Table III for
daunomycin. There is a good agreement between the effects
of these 15 Cs derivatives on colchicine, vincristine and
daunomycin resistance. Some Cs derivatives could overcome
colchicine, vincristine and daunomycin resistance, thus giving
an IC50 + for MDR cells similar to the IC50 ofparental cells:
CsA, CsG, (Me-Ala6)-Cs, O-Acetyl-CsA, (O-tBu-Ser8)-Cs,
(Me-Ile")-Cs and (3'deoxy-3'-oxo-MeBmt')-Cs.
No correlation was found between the immunosuppressive
and MDR sensitising properties of these 15 derivatives. Some
Cs were both immunosuppressive and active in MDR (CsA,
CsG, (Me-Ala6)-Cs), some were immunosuppressive but inac-
tive in MDR ((D-Ser8)Cs, (dhBmt-l,x-S-Me-Sar3,Val2)-Cs,
(8'Methoxy-dh-MeBmt')Cs, dihydroCsC), some were non-
immunosuppressive but active in MDR (O-acetyl-CsA,
J
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Table I Effect of the immunosuppressive and non-immunosuppressive Cs derivatives on susceptibility to colchicinea
IC5Oparental cells IC50 MDR cells
(ng ml-') (_ s.d.) (ngml-') (± s.d.)
Immuno-
Cs derivative No.b IC,0 + IC50 - Gainc IC,0 + IC,0 - P Gainc suppressiond
CsA 9 3.0(0.9) 31.7(10) 10.6 230(170) 1980(600) < 0.001 8.6 + + + + +
CsG 3 3.7(0.3) 30.7(5.2) 8.3 27.5(7) 2000(100) < 0.001 72.7 + + + +
(Me-Ala6)-Cs 2 4.1(0.1) 31.5(7.8) 7.7 46(5.6) 1900(0) < 0.001 41.3 + +
(D-Ser8)-Cs 2 4.5(1.3) 32.7(16) 7.3 1800(280) 1920(320) > 0.1 1.1 + + + +
(dhBmt-loc-S-Me-Sar,Val2)-Cs 2 3.5(1.7) 29.2(0.4) 8.3 740(80) 1750(141) < 0.001 2.4 + + + +
(8'Methoxy-dh-MeBmt')-Cs 2 5.9(0.1) 36.5(11) 6.2 1620(110) 1780(110) < 0.05 1.1 + + +
dihydroCsC 3 3.1(0.8) 45.7(5.1) 14.7 990(300) 2000(100) > 0.1 2.0 + + + + +
O-Acetyl-CsA 3 3.8(0.9) 28.3(7.4) 7.4 71(11) 2250(460) < 0.001 31.7 -
(O-tBu-Ser8)-Cs 5 2.6(0.6) 34.1(13) 13.1 22.3(3) 2050(100) < 0.001 91.9 -
(Me-Ile")-Cs 4 2.8(0.9) 30.6(4.1) 10.9 58.5(11) 2060(420) < 0.001 35.2 -
(3'-deoxy-3'-oxo-MeBmt')-Cs 5 3.3(0.7) 35.4(3.3) 10.7 21.5(3) 1733(104) < 0.001 80.6
(Pro3)-Cs 2 3.3(0.6) 36.0(14.1) 10.9 257(60) 1825(106) < 0.001 7.1
(O-Acetyl-Thr2)-Cs 6 3.6(0.8) 34.3(12) 9.5 550(340) 2130(300) 0.001 3.9
CsH 4 5.3(0.9) 36.2(11) 6.8 1630(1010) 2080(1100) > 0.1 1.3 _
N-phenyl-aminothio-carbamoyl-CsA 3 20.7(2.9) 30.7(5.2) 1.5 2080(240) 2420(600) > 0.1 1.2
aParental and MDRcelllines (400cellsperwelland 800cellsperwell, respectively) were incubatedwithcolchicineand theCsderivatives for6days.
Cell proliferation was measured by the MTT assay. The IC50 + and IC50 - were thecolchicine-IC50s in the presence and absence ofCs at I jog ml-'
(mean ± s.d. ofindicatedindependentexperiments). IC50differenceswerecalculated by Student's ttestversusthemeansofall EtOH solventcontrols:
forparental cells, with all Cs derivatives P<0.001. bNumber ofindependentexperiments (each in triplicate). cGains ofsensitivity were defined by the
ratio IC50 -/IC50+ . d_, non-immunosuppressive derivative; + + + to + + + + +, very immunosuppressive derivative.
Table II Effect of the immunosuppressive and non-immunosuppressive Cs derivatives on susceptibility to vincristine
IC50 parental cell IC5,0 MDR cells
(ng ml-') (± s.d.) (ngml-') (± s.d.)
Cs derivative No. IC50 + IC50 - Gain IC50 + IC50 - P Gain
CsA 5 4.6(1.5) 74.1(27) 16.1 65(45) 2440(1780) < 0.001 37.5
CsG 6 4.6(1.6) 74.5(28) 16.2 38.3(21) 2258(1619) < 0.001 59.0
(Me-Ala6)-Cs 2 5.7(0) 75.0(17) 13.2 57.5(5) 1825(106) < 0.001 31.7
(D-Ser8)-Cs 2 5.4(1.9) 85.0(13) 15.7 1800(0) 1925(106) > 0.1 1.1
(dhBmt-la-S-Me-Sar ,Val2)-Cs 2 6.7(0.4) 79.5(12) 11.9 1315(21) 1850(141) < 0.01 1.4
(8'Methoxy-dh-MeBmt')-Cs 2 16(0.7) 79.5(12) 5.0 1725(35) 1850(141) > 0.1 1.1
dihydroCsC 2 4.9(0.4) 85.0(12) 17.3 840(295) 1925(106) < 0.01 2.3
O-Acetyl-CsA 2 7.4(0.3) 79.5(12) 10.7 58(3) 1850(141) < 0.001 31.9
(O-tBu-Ser8)-Cs 2 5.7(0.3) 75.0(17) 13.2 50(11) 1845(35) < 0.001 36.9
(Me-Ile")-Cs 2 5.6(0.1) 75.0(17) 13.4 51.5(2) 1825(106) < 0.001 35.4
(3'-deoxy-3'-oxo-MeBmt')-Cs 2 6.1(0.4) 75.0(17) 12.3 92.5(56) 1845(35) < 0.001 19.9
(Pro')-Cs 2 5.7(0.1) 75.0(17) 13.2 270(28) 1825(106) < 0.001 6.8
(O-Acetyl-Thr')-Cs 2 6.1(0.3) 85.0(13) 13.9 360(57) 1925(106) < 0.001 5.3
CsH 2 23.8(4.6) 170(7) 7.1 3500(3535) 3950(2616) > 0.1 1.1
N-phenyl-aminothio-carbamoyl-CsA 3 54(5.1) 86.7(34) 1.6 1050(377) 1200(436) < 0.01 1.1
Samelegend as forTable I. IC50 differences werecalculatedby Student's t test. Forparentalcells, with all Csderivatives, P<0.001 versusthe EtOH
solvent control.
Table III Effect of the immunosuppressive and non-immunosuppressive Cs derivatives on susceptibility to daunomycin
IC50parental cells IC50 MDR cells
(ngml-') ( s.d.) (ngml-') (± s.d.)
Cs derivative No. IC50 + IC50- Gain IC50+ IC50 - P Gain
CsA 6 2.8(0.9) 19.9(3.2) 7.1 34.2(29) 1080(630) < 0.001 31.6
CsG 4 3.6(0.7) 22.1(5.9) 6.1 26.1(10) 1987(103) < 0.001 76.1
(Me-Ala6)-Cs 2 3.6(0.1) 19.0 (0) 5.3 25.5(0.7) 1825(318) < 0.001 71.6
(D-Ser8)-Cs 2 4.6(0.9) 21.5(2.1) 4.7 1775(176) 2175(353) > 0.1 1.2
(dhBmt-la-S-Me-Sar,Val2)-Cs 2 4.3(0.1) 19.5(1.4) 4.5 850(42) 2100 (0) < 0.001 2.5
(8'Methoxy-dh-MeBmt')-Cs 2 5.4(0.6) 19.5(1.4) 3.6 1725(106) 2100 (0) > 0.1 1.2
dihydroCsC 2 3.3(0.3) 21.5(2.1) 6.5 1000(707) 2175(357) > 0.1 2.2
O-Acetyl-CsA 2 3.6(0.2) 19.5(1.4) 5.4 22(0.7) 2100 (0) < 0.001 95.4
(O-tBu-Ser8)-Cs 2 3.1(0.4) 19.2(1.1) 6.2 30(23) 2075 (35) < 0.001 69.2
(Me-Ile'')-Cs 2 3.6(0.4) 19.0 (0) 5.3 19.7(2.5) 1825(318) < 0.001 92.6
(3'-deoxy-3'-oxo-MeBmt1)-Cs 2 3.4(0.2) 19.2(1.1) 5.6 40.2(31) 2075 (35) < 0.001 51.6
(Pro')-Cs 2 3.9 (0) 19.0 (0) 4.9 152(3) 1825(318) < 0.001 12.0
(O-Acetyl-Thr')-Cs 2 2.9(0.3) 21.5 (21) 7.4 195(148) 2175(353) < 0.001 11.1
CsH 2 5.3(0.1) 25.5(4.9) 4.8 940(933) 1120(679) > 0.1 1.2
N-phenyl-aminothio-carbamoyl-CsA 3 12.7(3.2) 18.2(3.7) 1.4 606(190) 766(252) < 0.01 1.3
Same legend as for Table I. IC50 differences were calculated by the Student's t test. For parental cells, P<0.001 with all Cs derivatives except
N-phenyl-aminothio-carbamoyl-CsA (P<0.05) versus the EtOH solvent control.870 C. GAVERIAUX et al.
(Me-Ile'l)-Cs, (O-tBu-Ser8)-Cs, (3'desoxy-3'-oxo-MeBmt')-Cs,
(Pro)3-Cs, (O-acetyl-Thr2)-Cs), and some were non-
immunosuppressive and inactive in MDR (CsH, N-phenyl-
aminothio-carbamoyl-IsoCsA). All these Cs derivatives
showed little activity on MDR cells at lower concentration
(0.1Ig ml', data not shown).
Some Cs of both the immunosuppressive category (CsG,
(Me-Ala6)-Cs) and the non-immunosuppressive category ((O-
tBu-Ser8)-Cs, (Me-Ile")-Cs, (3'deoxy-3'oxo-MeBmt')-Cs)
were more active than CsA in MDR neutralisation.
Irrespective of the high gains of sensitivity obtained with
MDR cells, the highest gain measured for parental cells was
17, which seems to be the maximum gain achievable. This
corresponds to respective IC_0s for colchicine, vincristine and
daunomycin of 2-3ngml[', 4-6ngml-' and 3-4ng-ml[',
in the presence of the Cs derivatives. In the case of MDR
cells, even a gain of 100, in the presence of the Cs derivative,
corresponds to an IC5o for colchicine or daunomycin of
about 20 ng ml-'.
Discussion
The use of cyclosporin A to overcome multidrug resistance of
tumour cells has been reported by several investigators.
Slater et al. (1986b) described some effect of CsA at
3.3 tg ml-' on vincristine and daunorubicin susceptibility of
MDR acute lymphatic leukaemia cells but not of parental
cells, whereas little effect was found for daunorubicin suscep-
tibility of parental and MDR Ehrlich ascites carcinoma cells
(about a 2-fold increase in sensitivity) (Slater et al., 1986a).
Meador et al. (1987) found some effect of CsA at 1 ,tg ml-'
in drug sensitive Ehrlich ascites carcinoma and murine
hepatoma 129 cell lines, although this effect was small com-
pared to our experiments. Twentyman et al. (1987) first
indicated some agreement between the immunosuppressive
and the MDR sensitising properties of four Cs derivatives,
but they later demonstrated (1988), using further non-
immunosuppressive derivatives, that these two properties
could be dissociated.
Using similar assay systems and cell lines whose MDR
phenotype dependence on Pgp-mediated efflux is well estab-
lished (Kartner et al., 1983), we found that CsA decreased
resistance to all three drugs colchicine, vincristine and
daunomycin (Figure 1): it not only decreased the ICso of the
drugs in MDR cells, but also in parental cells. Experiments
in progress, using several other cell lines from which both
parental and MDR lines are available, show that chemosen-
sitisation of 'parental' cells by CsA (or Cs-derivatives) is not
a common property (results not shown). The parental CHO
cell line has IC50s in the orders of 30 ng nl1' for colchicine,
80 ng ml-' for vincristine and 20 ng ml' for daunomycin,
which is about 10-fold higher than IC_, measured for other
parental cells as well as for normal cells. Perhaps the cells of
the parental CHO line express small amounts of Pgp, confer-
ring upon them a weak multidrug resistance, thus making
them somewhat susceptible to chemosensitisation down to
the normal IC50 limit observed with these drugs in other cells
which do not contain Pgp.
Interestingly, our experiments showed differential effects of
CsA on MDR attenuation depending on the anti-tumour
drug tested; indeed, the MDR gains for vincristine,
daunomycin and colchicine were 77, 47 and 14 respectively in
experiments run in parallel (Figure 1). Thus, CsA-mediated
chemosensitisation was not as strong for colchicine as for
daunomycin and vincristine. CsA reversed vincristine and
daunomycin resistance of MDR cells completely, but only
part of their colchicine resistance. Such differential chemosen-
sitisation capacities for various anti-cancer drugs had already
been observed with quinacrine (Inaba & Maruyama, 1988)
and with the calcium channel blocker Verapamil (Beck et al.,
1986).
The non-immunosuppressive cyclosporin, CsH, was inac-
tive at1 .gml-' in reversing colchicine and vincristine resis-
tance but slightly active for daunomycin resistance of MDR
cells, extending the data of Twentymx?n et al. (1987) on the
decrease of adriamycin resistance with 5,Lgml-' of this com-
pound. However, it slightly potentiated the inhibitory effects
of all three drugs on parental cells. The latter characteristic
may be due to the easier neutralisation by CsH of the
presumed lower levels of Pgp present in parental cells.
Since the MDR cells contain much more Pgp than the
parental cells (Van der Blieket al., 1986; Scheper et al.,
1988), it can indeed be expected that limiting amounts of Cs
derivatives, endowed with a low Pgp-neutralising capacity,
will show stronger effects on the parental cells than on the
MDR cells. Some other Cs derivatives ((D-Ser8)-Cs and (8'-
Methoxy-dh-MeBmtl)-Cs) even gave detectable gains of sen-
sitivity with the low-Pgp parental cells whereas no effect was
found with high-Pgp MDR cells.
We found no correlation between the immunosuppressive
activity and the MDR-neutralising activity of more than
120 Cs derivatives (and of about 100 structurally related
molecules) tested so far. As shown here for 15 derivatives
tested on CHO cells in which the MDR property is definitely
caused by Pgp-mediated drug efflux, four Cs derivative
categories can be defined, some sharing both immunosupp-
ressive and MDR-neutralising activities, some showing only
one and some others being devoid of both activities. We thus
confirm and extend the well documented results of Twen-
tyman (1988), who showed the chemosensitising properties of
poorly or non-immunosuppressive Cs derivatives on drug
resistant H69 cells, as well as those of Haitet al. (1987) and
Chambers et al. (1988), who mentioned some chemosensitis-
ing activity of one non-immunosuppressive Cs.
For the four non- or weakly immunosuppressive Cs
derivatives used by Twentyman (1988) on parental and MDR
H69 cells, the decreasing order of efficacy for chemosensitisa-
tion towards adriamycin and vincristine was the following:
O-Acetyl-CsA>(Me-Ile")-Cs>CsA>(Me-Ala6)-Cs. In our
hands, and considering only non-immunosuppressive Cs
derivatives, (Me-Ile")-Cs and 0-acetyl-CsA gave the highest
chemosensitisation to daunomycin whereas (0-tBu-Ser8)-Cs
and (Me-Ile")-Cs gave the highest chemosensitisation to vinc-
ristine, and finally (0-tBu-Ser8)-Cs and (3'-deoxy-3'-oxo-
MeBmt')-Cs gave the highest chemosensitisation to col-
chicine. From our results and those of Twentyman (1988), it
thus appears that a given Cs derivative which may be the
best to overcome resistance to one anti-tumour drug is not
necessarily as effective in overcoming the resistance to several
anti-tumour agents.
Since immunosuppressive Cs derivatives bind to the 'in-
tracellular receptor' cyclophilin, whereas non-immuno-
suppressive Cs do not (Handschumacher et al., 1984;
Quesniaux et al., 1987), cyclophilin appears not to be
involved in MDR. Naito and Tsuruo (1989) have demon-
strated that CsA was as effective as vinblastine for the inhibi-
tion of the high affinity binding of vincristine to plasma
membranes of MDR K562 cells. Whether the MDR active
and inactive Cs actually decrease the anti-tumour drug efflux
out of the cell and bind to the Pgp might help to elucidate
the mechanism of action of Cs in MDR. Patients who
require immunosuppression for organ transplantation or
autoimmunity treatment might benefit from being treated
with Cs derivatives which do not affect the function of their
normal Pgp. In this regard, it is important that some
immunosuppressive Cs such as (D-Ser8)-Cs, (dhBmt-lla-S-
Me-Sar3, Val2)-Cs and (8'Methoxy-dh-MeBmt')-Cs, are com-
pletely devoid of MDR sensitising properties.
The prime interest for clinical cancer therapy will be the
identification of non-immunosuppressive Cs derivatives with
very potent MDR neutralising activity, good phar-
macokinetic properties in vivo, but that are devoid of toxic
effect on normal cells.
We are very grateful to Dr Jean Borel who drew our attention to this
new property of cyclosporin.OVERCOMING MDR BY CSA AND DERIVATIVES 871
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